Ballicules.com

Sarilumab

KEVZARA

What it isIL-6 receptor antibody; rheumatoid arthritis and polymyalgia rheumatica.

Why this oneIt is the IL-6-receptor blocker specifically labeled for polymyalgia rheumatica when corticosteroids fail or cannot be tolerated.

What limits itIt suppresses CRP and fever, so infection can be masked. Neutropenia, transaminitis and GI perforation risk.

FDA-approved for

FDA label

BOXED WARNING Risk of serious infections (bacterial, TB, invasive fungal, opportunistic) that may lead to hospitalization or death; avoid in active infection
FDA dosingPopulationStartTargetMax
Rheumatoid arthritisAdult200 mg SC q2wk200 mg SC q2wk200 mg SC q2wk
Polymyalgia rheumaticaAdult200 mg SC q2wk (with tapering corticosteroids)200 mg SC q2wk200 mg SC q2wk
Polyarticular juvenile idiopathic arthritis (≥63 kg)Pediatric200 mg SC q2wk200 mg SC q2wk200 mg SC q2wk

Renal Undefined

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy Insufficient human data; monoclonal antibody actively crosses placenta in 3rd trimester and may affect infant immune response

Lactation No data on presence in human milk; maternal IgG is present in milk

⚠ BOXED WARNING

Cost, est. cash$1,000–$15,000+/month

Generic entry2033 est. (biosimilar)

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4

Legacy pregnancy categoryNot assigned — PLLR-era drug

Defining liabilitySerious infection, cytopenias, hepatic injury and malignancy risk require laboratory and clinical monitoring.

Mechanism of action: Sarilumab ballicule

Sarilumab ballicule: receptor binding, kinetics and half-life diagram

Open Sarilumab in the interactive console ↗

Memory aids: mascots and interaction avatars

Sarilumab no kinetic interactions avatar
no kinetic interactions

Open Sarilumab in the interactive console ↗